Peptide Fab Ligands for Mild Antibody Fragment Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current purification methods for multi-specific monoclonal antibodies (msAbs) and their fragments are inadequate due to the limitations of Protein A and Protein L, which are costly, biochemically unstable, and require harsh elution conditions, failing to effectively isolate Fab-κ2 and Fab-λ subtypes.
Innovation Solution
Development of novel peptide ligands targeting the Fab domain and scFv, comprising specific amino acid sequences, which facilitate their purification by binding to support materials such as chromatography resins, polymer surfaces, and microfluidic devices, utilizing mild elution conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Protein A or Protein L is used for purification, then binding capacity is achieved, but cost is high and biochemical stability is poor
Solution Approach 1:
The patent creates simplified peptide copies of the binding sites of Protein A and Protein L. Instead of using the entire complex protein structures, the invention identifies and reproduces only the essential amino acid sequences that provide Fab-binding activity. This copying approach maintains the functional binding capability while dramatically reducing complexity, improving stability, and lowering manufacturing costs.
Solution Approach 2:
The patent employs short peptide sequences (12-20 amino acids) instead of large proteins. These peptides are chemically synthesized rather than expressed biologically, making them cheaper to produce, more stable, and easier to manufacture at scale. The peptides can be directly conjugated to solid supports to create reusable purification media.
2Ease of operation
If Protein A or Protein L is used for purification, then binding activity is achieved, but harsh elution conditions are required
Solution Approach 1:
The patent designs peptides with specific local amino acid compositions that provide binding activity through localized interactions. The peptides contain specific motifs (such as aromatic and charged residues) that engage in localized hydrophobic and electrostatic interactions with the Fab domain, allowing for selective binding that can be reversed under milder conditions compared to the extensive interactions required for Protein A/L binding.
Solution Approach 2:
The patent utilizes peptides with tunable binding affinities through sequence optimization. By adjusting amino acid composition, length, and structure, the binding strength can be modulated to achieve adequate capture while allowing elution under milder conditions (e.g., lower pH, lower ionic strength) that preserve product stability.
3Adaptability or versatility
If Protein L is used for purification, then Fab-κ binding is achieved, but Fab-λ and other subtypes are not bound
Solution Approach 1:
The patent develops peptide ligands with universal binding capability across multiple Fab subtypes (κ and λ light chains). The peptide sequences are designed to recognize conserved structural features of the Fab domain that are common across different antibody isotypes, enabling a single peptide ligand to bind multiple target variants. This universal binding approach maintains selectivity for Fab regions while accommodating diversity in light chain types.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide ligands achieve high binding capacity and purity of Fab and scFv-containing proteins, offering cost-effective and stable purification comparable to commercial resins, with yields and purities exceeding 70% and 70%, respectively.
Implementation Method 1
novel peptide ligands capable of targeting the fragment antigen binding (Fab) domain and/or single-chain variable fragment (scFv) to facilitate the isolation and/or purification of Fab- and/or scFv-containing proteins or polypeptides
Implementation Method 2
The novel ligands disclosed herein are capable of universal and subtype-specific biorecognition
Data Source
AI summary
The present disclosure provides compositions and methods related to the purification and/or isolation of antibodies. In particular, the present disclosure provides novel peptide ligands capable of targeting the fragment antigen binding (Fab) domain and/or single-chain variable fragment (scFv) of antibodies to facilitate the isolation and/or purification of antibodies from processing fluid streams. The novel ligands disclosed herein are capable of universal and subtype-specific biorecognition.